

U.S. Patent Application No. 10/697,551  
Amendment dated November 10, 2006  
Reply to Office Action of May 11, 2006

**REMARKS/ARGUMENTS**

Reconsideration and continued examination of the above-identified application are respectfully requested.

By way of this amendment, claims 1-15 and 17-27 are pending. Claim 16 has been canceled. New claims 20-27 have been added by way of this amendment. Further, claims 1, 2, and 17 have been amended. In particular, claims 1 and 17 recite that the polyvinylpyrrolidone has a K value of from 80 to about 150. Claim 2 recites a narrower range. The new claims recite various amounts of the polyvinylpyrrolidone or amounts of the oxazoline polymer. Full support for these amendments can be found in the present application, for instance, at paragraph [0027], paragraph [0018] last two lines, paragraph [0024], and paragraph [0025], as well as the examples and, in particular, Table 1, which specifically recites K value ranges for polyvinylpyrrolidones that can be used in the present application and, in particular, note the K values for PVP K-90 and PVP K-120, which encompasses a range of 80 - 130 and paragraph [0024], which recites K values on the order of an upper range of "about 150." Accordingly, no new matter is introduced by way of this amendment and entry of this amendment is respectfully requested.

**Claim 19**

It is noted that claim 19 (as originally filed) was not included in any rejection in the present Office Action. Examination is respectfully requested.

**Rejection of Claims 1-18 under 35 U.S.C. §102(b) -- Pomplun et al.**

The Examiner, at page 2 of the Office Action, rejects claims 1-18 under 35 U.S.C. §102(b) as being anticipated by Pomplun et al. (UK Patent Application No. GB 2,122,209 A). The

U.S. Patent Application No. 10/697,551  
Amendment dated November 10, 2006  
Reply to Office Action of May 11, 2006

Examiner asserts that Pomplun et al. shows a creping process using a creping adhesive which contains PVP and a high molecular polymer. The Examiner makes specific reference to the abstract and page 1, lines 71-124. The Examiner asserts that since the creping adhesive described in Pomplun et al. does not discuss the presence of ethoxylated acetylenic diol or oxazoline, this would mean that no ethoxylated acetylenic diol or oxazoline polymer are present. Thus, the Examiner asserts that Pomplun et al. would show the process set forth in claim 1 of the present application.

With respect to the remaining claims, the Examiner asserts that Pomplun et al. shows the use of a PVP manufactured by GAF which would satisfy the various parameters set forth in claims 2-9 relating to the K value,  $T_g$ , average molecular weight, and the amount of PVP present in the adhesive. The Examiner further asserts that since epichlorohydrin is not mentioned, Pomplun et al. would show an adhesive that does not contain epichlorohydrin. For the following reasons, this rejection is respectfully traversed.

With respect to claims 1 and 17, these claims recite that the polyvinylpyrrolidone has a K value of 80 to about 150. As indicated by the Examiner, Pomplun et al., at most, shows a K-30 polyvinylpyrrolidone and makes no other mention of any other types of polyvinylpyrrolidone. Further, Pomplun et al. provides no teaching or suggestion that significantly higher K values would be acceptable in a creping process and a K-30 PVP is significantly different from K values of 80 or higher.

In addition, with respect to some of the new dependent claims, there is no teaching or suggestion in Pomplun et al. regarding an embodiment where the polyvinylpyrrolidone is present in the adhesive in an amount of about 100 wt%.

For these reasons, this rejection should be withdrawn.

U.S. Patent Application No. 10/697,551  
Amendment dated November 10, 2006  
Reply to Office Action of May 11, 2006

**Rejection of Claims 1, 6-13, and 16-18 under 35 U.S.C. §102(b) and §103(a) -- Warchol et al.**

At the bottom of page 3 of the Office Action, the Examiner then rejects claims 1, 6-13, and 16-18 under 35 U.S.C. §102(b) as being anticipated by or, in the alternative, under 35 U.S.C. §103(a) as obvious over Warchol et al. (U.S. Patent No. 5,633,309). The Examiner asserts that Warchol et al. shows a creping adhesive which shows a low amount of an oxazoline polymer. The Examiner asserts that while the creping adhesive indicates the presence of a polyoxazoline of from 1% to 5 wt%, after this amount is diluted with the water, as mentioned at col. 4, lines 43-48 of Warchol et al., the amount of oxazoline polymer would be less than 1 wt%. Further, the Examiner asserts that the remaining details of the claims would be obvious in view of Warchol et al. For the following reasons, this rejection is respectfully traversed.

As indicated above, Warchol et al. does not teach or suggest a method which uses a polyvinylpyrrolidone having a K value of 80 to 150, nor provides any teaching or suggestion as to the desirability of having such K values for the creping methods of the present invention. For this reason alone, this rejection should be withdrawn.

In addition, with respect to the new dependent claims, certainly, while Warchol et al. indicates that the polyamide resin can be a general polyamide resin, the only specific examples given in Warchol et al. is a polyamide resin with an epichlorohydrin resin. Thus, Warchol et al. for this additional reason would not teach or suggest the subject matter of claims 8, 9, 18, and 19 of the present application, which recite no chloride and no epichlorohydrin. Furthermore, the amounts provided in some of the new dependent claims with respect to the oxazoline polymer are equally not taught or suggested by Warchol et al., wherein these claims recite an oxazoline polymer in an amount of less than 0.5 wt% or even lower or no oxazoline polymer at all. For these additional reasons, these claims are not taught or suggested by Warchol et al.

U.S. Patent Application No. 10/697,551  
Amendment dated November 10, 2006  
Reply to Office Action of May 11, 2006


Accordingly, for these reasons, the rejection should be withdrawn.

**CONCLUSION**

In view of the foregoing remarks, the applicant respectfully requests the reconsideration of this application and the timely allowance of the pending claims.

If there are any other fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0925. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such extension is requested and should also be charged to said Deposit Account.

Respectfully submitted,



Luke A. Kilyk  
Reg. No. 33,251

Atty. Docket No. 3597-143  
KILYK & BOWERSOX, P.L.L.C.  
400 Holiday Court, Suite 102  
Warrenton, VA 20186  
Tel.: (540) 428-1701  
Fax: (540) 428-1720